Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Rochester, United States. In Am J Hematol, Jan 2016
In 2005, William Vainchenker and others described a Janus kinase 2 mutation (JAK2V617F) in MPN and this was followed by a series of additional descriptions of mutations that directly or indirectly activate JAK-STAT: JAK2 exon 12, myeloproliferative leukemia virus oncogene (MPL) and calreticulin (CALR) mutations.
Pacritinib: a new agent for the management of myelofibrosis?
London, United Kingdom. In Expert Opin Pharmacother, 2014
INTRODUCTION: Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F, MPL, CALR) and constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway.
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pavia, Italy. In Am J Hematol, 2012
genetic association studies in Italian population: Data suggest that JAK2 GGCC haplotype is associated with JAK2 mutation (V617F) but is not associated with MPL mutation in exon 10 in myeloproliferative neoplasm subjects. [meta-analysis included]